{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:27:35Z","timestamp":1740130055067,"version":"3.37.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T00:00:00Z","timestamp":1570233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CODAR","award":["9316"],"award-info":[{"award-number":["9316"]}]},{"name":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda-Grupo de Estudio del SIDA"},{"name":"SEIMC"},{"name":"GESIDA"},{"name":"Janssen Cilag S.A."},{"name":"Red de Investigacion en Sida","award":["RIS-EST29","RD12\/0017\/0001","RD12\/0017\/0005","RD17\/0017\/0022","RD17\/0017\/0029"],"award-info":[{"award-number":["RIS-EST29","RD12\/0017\/0001","RD12\/0017\/0005","RD17\/0017\/0022","RD17\/0017\/0029"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Darunavir\/cobicistat can be used as mono, dual, triple or more than triple therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess factors associated with the number of drugs in darunavir\/cobicistat regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A nationwide retrospective cohort study of consecutive HIV-infected patients initiating darunavir\/cobicistat in Spain from July 2015 to May 2017. Baseline characteristics, efficacy and safety at 48\u2009weeks were compared according to the number of drugs used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 761 patients (75% men, 98% were antiretroviral-experienced, 32% had prior AIDS, 84% had HIV RNA &amp;lt;50\u2009copies\/mL and 88% had \u2265200 CD4 cells\/mm3) who initiated darunavir\/cobicistat as mono (n=308, 40%), dual (n=173, 23%), triple (n=253, 33%) or four-drug (n=27, 4%) therapy. Relative to monotherapy, triple therapy was more common in men aged &amp;lt;50\u2009years, with prior AIDS and darunavir plus ritonavir use, and with CD4 cells &amp;lt;200\/mm3 and with detectable viral load at initiation of darunavir\/cobicistat; dual therapy was more common with previous intravenous drug use, detectable viral load at initiation of darunavir\/cobicistat and no prior darunavir plus ritonavir; and four-drug therapy was more common with prior AIDS and detectable viral load at initiation of darunavir\/cobicistat. Monotherapy and dual therapy showed a trend to better virological responses than triple therapy. CD4 responses and adverse effects did not differ among regimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Darunavir\/cobicistat use in Spain has been tailored according to clinical characteristics of HIV-infected patients. Monotherapy and dual therapy have been common and preferentially addressed to older patients with a better HIV status, suggesting that health issues other than HIV infection may have been strong determinants of its prescription.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz399","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T07:47:33Z","timestamp":1567151253000},"page":"208-214","source":"Crossref","is-referenced-by-count":4,"title":["Factors associated with the number of drugs in darunavir\/cobicistat regimens"],"prefix":"10.1093","volume":"75","author":[{"given":"Esteban","family":"Martinez","sequence":"first","affiliation":[{"name":"Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Negredo","sequence":"additional","affiliation":[{"name":"Hospital Universitari Germans Trias i Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[{"name":"Hospital del Mar, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ocampo","sequence":"additional","affiliation":[{"name":"Hospital Alvaro Cunqueiro, Vigo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Sanz","sequence":"additional","affiliation":[{"name":"Hospital Universitario Principe de Asturias, Alcala de Henares, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Garcia-Fraile","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Princesa, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Martin-Carbonero","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Lozano","sequence":"additional","affiliation":[{"name":"Hospital Virgen de Valme, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen M","family":"Gonzalez-Domenech","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de la Victoria, Malaga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Montero","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Politecnico La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Boix","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Alicante, Alicante, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Payeras","sequence":"additional","affiliation":[{"name":"Hospital Sont Llatzer, Palma de Mallorca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Torralba","sequence":"additional","affiliation":[{"name":"Hospital Universitario de Guadalajara, Guadalajara, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonzalez-Cordon","sequence":"additional","affiliation":[{"name":"Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Moreno","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen","family":"Alejos","sequence":"additional","affiliation":[{"name":"Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5700-5257","authenticated-orcid":false,"given":"Maria J","family":"Perez-Elias","sequence":"additional","affiliation":[{"name":"Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"GeSIDA 9316 CODAR Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Jes\u00fas","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen","family":"Alejos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Negredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"de los Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz Martin","family":"Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Mar\u00eda","family":"Gonz\u00e1lez-Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Boix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Payeras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Torralba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Vilanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Garcia-Fraile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"de La Fuente Moral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Garcia","family":"de Lomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Gracia Mateo","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Tasias","family":"Pitatch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos Diez","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Raya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Troya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonia","family":"Sep\u00falveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santos","family":"del Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Jes\u00fas","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina Gomez","family":"Ayerbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gonzalez-Cordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Callau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhon","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,5]]},"reference":[{"key":"2019121310473400500_dkz399-B1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med"},{"key":"2019121310473400500_dkz399-B2","first-page":"215","article-title":"First-line boosted protease inhibitor-based regimens in treatment-naive HIV-1-infected patients\u2014making a good thing better","volume":"11","author":"Llibre","year":"2009","journal-title":"AIDS Rev"},{"year":"2019","key":"2019121310473400500_dkz399-B3"},{"year":"2018","key":"2019121310473400500_dkz399-B4"},{"year":"2018","key":"2019121310473400500_dkz399-B5"},{"key":"2019121310473400500_dkz399-B6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2019121310473400500_dkz399-B7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jac\/dkw437","article-title":"Impact of polypharmacy on antiretroviral prescription in people living with HIV","volume":"72","author":"Guaraldi","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2019121310473400500_dkz399-B8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/QAD.0b013e3283348944","article-title":"The MONET trial: darunavir\/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies\/mL","volume":"24","author":"Arribas","year":"2010","journal-title":"AIDS"},{"key":"2019121310473400500_dkz399-B9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hiv.12386","article-title":"Week 96 efficacy and safety of darunavir\/ritonavir monotherapy vs. darunavir\/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial","volume":"18","author":"Girard","year":"2017","journal-title":"HIV Med"},{"key":"2019121310473400500_dkz399-B10","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","article-title":"Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 trial","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019121310473400500_dkz399-B11","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"2019121310473400500_dkz399-B12"},{"key":"2019121310473400500_dkz399-B13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/hiv.12530","article-title":"Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia","volume":"18","author":"Echeverria","year":"2017","journal-title":"HIV Med"},{"key":"2019121310473400500_dkz399-B14","first-page":"543.e1","article-title":"GESIDA\/National AIDS Plan: consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2015)","volume":"33","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2019121310473400500_dkz399-B15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eimc.2016.02.028","article-title":". Executive summary of the GESIDA\/National AIDS plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2016)","volume":"34","year":"2016","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2019121310473400500_dkz399-B16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.eimc.2017.04.001","article-title":". Executive summary of the GESIDA\/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2017)","volume":"36","year":"2018","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2019121310473400500_dkz399-B17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","article-title":"A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients","volume":"32","author":"Eron","year":"2018","journal-title":"AIDS"},{"key":"2019121310473400500_dkz399-B18","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.qai.0000180077.59159.f4","article-title":"Lopinavir\/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study)","volume":"40","author":"Arribas","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019121310473400500_dkz399-B19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/QCO.0b013e3283422cdf","article-title":"Protease inhibitor monotherapy","volume":"24","author":"Perez-Valero","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"2019121310473400500_dkz399-B20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/jac\/dkt517","article-title":"Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group","volume":"69","author":"Curran","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2019121310473400500_dkz399-B21","doi-asserted-by":"crossref","first-page":"e0148924.","DOI":"10.1371\/journal.pone.0148924","article-title":"Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens","volume":"11","author":"L\u00f3pez-Cort\u00e9s","year":"2016","journal-title":"PLoS One"},{"key":"2019121310473400500_dkz399-B22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","article-title":"Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial","volume":"15","author":"Arribas","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2019121310473400500_dkz399-B23","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2019121310473400500_dkz399-B24","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000002320","article-title":"Uptake and effectiveness of two-drug compared to three-drug antiretroviral regimens among HIV-positive individuals in Europe","author":"Neesgaard","year":"2019","journal-title":"AIDS"},{"key":"2019121310473400500_dkz399-B25","doi-asserted-by":"crossref","first-page":"e1002424.","DOI":"10.1371\/journal.pmed.1002424","article-title":"Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: a prospective analysis of the D:A:D observational study","volume":"14","author":"Boyd","year":"2017","journal-title":"PLoS Med"},{"key":"2019121310473400500_dkz399-B26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hiv.12348","article-title":"Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials","volume":"17","author":"Arribas","year":"2016","journal-title":"HIV Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/1\/208\/31512984\/dkz399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/1\/208\/31512984\/dkz399.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T10:48:16Z","timestamp":1576234096000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/1\/208\/5581811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,5]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,10,5]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz399","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,10,5]]}}}